Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Platelet Lysate for PAD
NCT03297814Phase 2Unknown
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Biologic, Blood-derived biologic, Cell therapy supplement
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic platelet lysate in Peripheral Arterial Disease (PAD) (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Status: unknown.
02
Drugs
allogeneic platelet lysate
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03297814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297814.